Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Apelin/APLN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Native Ligand | Apelin/APLN Recombinant Peptide (Isoforms 12/13/17/36) High purity (>95%), Pyroglutamyl-modified options available. Sequence Verified. |
View APLN Products |
| Stabilized Variant | pGlu-Apelin-13 (N-terminal Pyroglutamyl) Protease-resistant variant for extended half-life studies. Endotoxin <1EU/ug. |
View APLN Products |
| Antigen / Mutant Protein | APLN Mutant / Truncated Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View APLN Products |
| Gene Delivery | APLN Promise-ORF / Lentivirus Full-length ORF for stable expression and pathway assays. |
View APLN Products |
| Benchmark Ab | Anti-Apelin Neutralizing Antibody (Sequence Verified) For ligand capture, PK/PD assays, and epitope mapping. |
View APLN Products |
| Validator | APLN siRNA Set Sequence-verified specific knockdown tools. |
View APLN Products |
| Receptor | APJ Receptor (APLNR/AGTRL1) Lentivirus Premade Particles Full-length GPCR for stable cell line construction. HEK293 expressed. |
View APLNR Products |
| Receptor Protein | APLNR-ECD-Fc Fusion Protein Extracellular domain for ligand binding assays (SPR/BLI). Human/Mouse/Cyno orthologs. |
View APLNR Products |
| Alternative Ligand | Elabela/Toddler (ELABELA) Alternative endogenous APLNR agonist for biased signaling comparison. |
View ELABELA Products |
| Pathway Partner | ACE2 Recombinant Protein Cardiovascular axis modulator; relevant for HFpEF combination studies. |
View ACE2 Products |
| Related Target | AGTR1 (Angiotensin II Receptor) Counter-regulatory pathway for cardiovascular tone profiling. |
View AGTR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Metabolic Stability & Half-life Optimization | pGlu-Apelin variants with verified N-terminal cyclization; Human plasma stability assay standards included |
| GPCR Biased Signaling (G-protein vs β-arrestin) | APLNR Lentivirus for stable PathHunter® cell line construction; Gi coupling validated by cAMP inhibition |
| Cross-species Translation (Human/Cyno/Mouse) | Ortholog-specific Apelin sequences with >98% homology; Species-specific APLNR-ECD proteins for off-target screening |
| Receptor Internalization/Trafficking | Full-length APLNR lentiviral particles with C-terminal tags for flow cytometry and confocal microscopy |
| Sub-Q Formulation Development | High-concentration (10-20 mg/mL) Apelin analogs available; Low endotoxin (<0.1EU/ug) for in vivo injection |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) with precise recombinant expression |
| Endotoxin Interference in Cell Assays | Endotoxin Controlled (<1EU/ug) manufacturing for all recombinant ligands |
Live Apelin/APLN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Apelin therapeutics is intensifying, with major players shifting focus from native peptide replacement to stabilized analogs and biased agonists. As first-generation therapies (Mezzion's urocotide/HM-15169) advance through Phase II for heart failure with preserved ejection fraction (HFpEF), the next wave of R&D is targeting metabolic syndrome, NASH, and pulmonary arterial hypertension through subcutaneously deliverable, long-acting formulations. Key inflection point: The transition from IV infusion to sub-Q dosing requires overcoming the native peptide's 4-minute plasma half-life through pyroglutamyl modification and lipid conjugation strategies, necessitating rigorous stability and immunogenicity assays.
Leading pharmaceutical companies such as Amgen, Bristol Myers Squibb (via Cardioxyl), Sanofi, and Novartis have active programs, underscoring the high interest in this pathway.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Stabilized Peptide Analogs | Mezzion (MM-201), Hanmi (HM-15169), Amgen, BMS | HFpEF, HFrEF, PAH | Plasma Stability Assay (Need Pyroglutamyl-Apelin reference standards) |
| Biased Small Molecules / Agonists | Novo Nordisk, Sanofi, Gila Therapeutics | Obesity, NASH, Metabolic Disorders | G-protein vs β-arrestin Pathway Selectivity (Need APLNR Stable Cell Lines) |
| Peptide-Conjugates / Fc-Fusion | Elpidera (acquired), Start-ups | PAH, CKD | Receptor Binding Affinity (Need APLNR-ECD-Fc for SPR/BLI) |
| Dual APJ/AT1 Modulators | Research Phase | Hypertension | Cross-reactivity Screening (Need AT1R vs APLNR selectivity panels) |
| Monoclonal Antibodies | Pre-clinical biotech | Cancer (Angiogenesis) | Epitope Mapping (Need Recombinant APLN variants) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
-
Metabolic Stability: Resistance to ACE2 and NEP cleavage. Pyroglutamyl (pGlu) modification at N-terminus is key. Assay: Human plasma stability, trypsin resistance. TarMart solution: pGlu-Apelin-13 (stabilized standard).
-
Biased Signaling: Preferential activation of Gi/cAMP pathway over β-arrestin recruitment to avoid receptor desensitization and tachyphylaxis. Assay: cAMP inhibition (Gi coupling), β-arrestin recruitment (PathHunter), ERK1/2 phosphorylation. TarMart: APLNR Lentivirus for stable cell lines.
-
Cross-species Translation: Human/Cyno/Mouse ortholog panels needed for preclinical bridging. TarMart: APLNR-ECD-Fc ortholog proteins.
-
Receptor Trafficking: Monitor APLNR internalization and recycling upon chronic treatment. TarMart: Full-length APLNR lentivirus with C-terminal tags for flow/imaging.
-
Formulation Feasibility: High-concentration (>10 mg/mL) sub-Q formulations require solution stability and low viscosity. TarMart: High-concentration Apelin analogs with low endotoxin.
Screening Assay Recommendations
| Screening Phase | Key Assay | TarMart Key Reagent |
|---|---|---|
| Hit Identification | Competitive binding vs radiolabeled Apelin | APLNR-ECD-Fc (Human/Cyno/Mouse) |
| Lead Optimization | Plasma stability (t1/2 determination) | pGlu-Apelin-13 (stabilized standard) |
| Mechanism | Biased signaling (cAMP vs β-arrestin) | APLNR Lentivirus (for stable cell line) |
| Safety | Off-target screening (ACE, AT1R, APJ homologs) | ACE2 Protein, AT1R-ECD (cross-target panel) |
| AD/PK | Immunogenicity detection (Anti-drug Ab) | Anti-Apelin Antibody (as capture reagent) |
Related Targets (Cross-Selling Pathway Partners)
Based on signaling pathway complementarity and combination therapy trends:
- APLNR (AGTRL1/APJ): The cognate receptor. Customer needs receptor protein for binding and lentivirus for cell lines. Pair with APLN for full ligand-receptor solution.
- ELABELA (Elabela/Toddler): Alternative endogenous APLNR agonist; different biased signaling profile; ideal control for biased screening.
- ACE2: Synergistic cardiovascular protection axis; relevant for HFpEF combination studies.
- AGTR1 (Angiotensin II Receptor): Counter-regulatory RAAS system; forms heterodimers with APJ; required selectivity screening.
Strategy: For HFpEF customers, bundle "Apelin ligand + APLNR receptor + ACE2 pathway protein" as a cardiovascular metabolic axis solution. For metabolic disease customers, highlight pGlu-Apelin-13 as a sub-Q formulation standard.